Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer
Authors
Keywords
<em class=EmphasisTypeItalic >MEK1</em> mutations, NSCLC, Central nervous system metastases, HRM-PCR, ASP-qPCR
Journal
Clinical & Translational Oncology
Volume 18, Issue 10, Pages 1039-1043
Publisher
Springer Nature
Online
2016-02-09
DOI
10.1007/s12094-016-1483-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- Mitogen-Activated Protein Kinase Signal Transduction in Solid Tumors
- (2014) Yuan-Yuan Lei et al. Asian Pacific Journal of Cancer Prevention
- MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking
- (2014) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
- (2014) Yiqing Qu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- MEK inhibition in non-small cell lung cancer
- (2014) Thomas E. Stinchcombe et al. LUNG CANCER
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages
- (2013) J. X. Zhou et al. ANNALS OF ONCOLOGY
- Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells
- (2013) Erika Martinelli et al. INTERNATIONAL JOURNAL OF CANCER
- MEK and the inhibitors: from bench to bedside
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- MEK in cancer and cancer therapy
- (2013) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic mutations of signaling genes in non-small-cell lung cancer
- (2010) Heather R. Sanders et al. CANCER GENETICS AND CYTOGENETICS
- Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma
- (2008) J. L. Marks et al. CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started